Back to Search
Start Over
Minimal manifestation status and prednisone withdrawal in the MGTX trial
- Source :
- Neurology, 95(6), E755-E766. LIPPINCOTT WILLIAMS & WILKINS, Neurology, Neurology, vol 95, iss 6
- Publication Year :
- 2020
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2020.
-
Abstract
- ObjectiveTo examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG).MethodsThis study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody–positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18–65 years at enrollment with disease duration less than 5 years. All patients received oral prednisone titrated up to 100 mg on alternate days until they achieved MMS, which prompted a standardized prednisone taper as long as MMS was maintained. The achievement rate of sustained MMS (no symptoms of MG for 6 months) with complete withdrawal of prednisone was compared between the thymectomy plus prednisone and prednisone alone groups.ResultsPatients with MG in the thymectomy plus prednisone group achieved sustained MMS with complete withdrawal of prednisone more frequently (64% vs 38%) and quickly compared to the prednisone alone group (median time 30 months vs no median time achieved, p < 0.001) over the 5-year study period. Prednisone-associated adverse symptoms were more frequent in the prednisone alone group and distress level increased with higher doses of prednisone.ConclusionsThymectomy benefits patients with MG by increasing the likelihood of achieving sustained MMS with complete withdrawal of prednisone.Clinicaltrials.gov identifierNCT00294658.Classification of evidenceThis study provides Class II evidence that for patients with generalized MG with AChR antibody, those receiving thymectomy plus prednisone are more likely to attain sustained MMS and complete prednisone withdrawal than those on prednisone alone.
- Subjects :
- Male
medicine.medical_treatment
Azathioprine
law.invention
0302 clinical medicine
Randomized controlled trial
Prednisone
law
Medicine
Single-Blind Method
030212 general & internal medicine
Young adult
Middle Aged
Thymectomy
Combined Modality Therapy
Substance Withdrawal Syndrome
3. Good health
Settore MED/26 - NEUROLOGIA
6.1 Pharmaceuticals
Anesthesia
adolescent
adult
animals
combined modality therapy
female
humans
immunosuppressive agents
male
middle aged
myasthenia gravis
prednisone
rats
single-blind method
substance withdrawal syndrome
thymoma
thymus neoplasms
young adult
thymectomy
Cognitive Sciences
Female
Immunosuppressive Agents
medicine.drug
Adult
Thymoma
Adolescent
Clinical Trials and Supportive Activities
Clinical Sciences
MGTX study group
Autoimmune Disease
Article
Young Adult
03 medical and health sciences
Rare Diseases
Clinical Research
Myasthenia Gravis
Post-hoc analysis
Animals
Humans
Neurology & Neurosurgery
business.industry
Neurosciences
Evaluation of treatments and therapeutic interventions
Thymus Neoplasms
medicine.disease
Myasthenia gravis
Rats
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 1526632X and 00283878
- Volume :
- 95
- Database :
- OpenAIRE
- Journal :
- Neurology
- Accession number :
- edsair.doi.dedup.....55e135ccd61185dd56db856ee5159f29